Micafungin — Complete Research Guide (2026)

Last updated 2026-06-30

What is Micafungin?

Micafungin is an echinocandin antifungal - a semisynthetic cyclic lipopeptide - administered intravenously in hospital (FDA-approved 2005 as Mycamine; also EMA-approved).

It is approved for candidaemia and invasive candidiasis, oesophageal candidiasis, and prophylaxis of Candida infections in patients undergoing haematopoietic stem-cell transplantation. Unlike caspofungin, micafungin is NOT approved for invasive aspergillosis. Its approval rests on pivotal human non-inferiority randomized controlled trials.

As a regulator-approved medicine, its efficacy and safety claims are grounded in clinical trial data rather than preclinical work.

How does Micafungin work?

Micafungin inhibits beta-(1,3)-D-glucan synthase, preventing formation of beta-1,3-glucan, an essential fungal cell-wall polysaccharide that has no human counterpart.

The resulting loss of cell-wall integrity is fungicidal against most Candida species; the fungal-specific target explains the class's generally favourable tolerability.

What does the research say about Micafungin?

• In a phase-3 double-blind trial, micafungin was non-inferior to liposomal amphotericin B for candidaemia and invasive candidiasis, with fewer treatment-related adverse events. ^[1]
• In a large randomized trial, micafungin was as effective as caspofungin for candidaemia and other forms of invasive candidiasis. ^[2]
• For antifungal prophylaxis during neutropenia after haematopoietic stem-cell transplantation, micafungin was superior to fluconazole. ^[3]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

• [1] Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial — Kuse ER et al., Lancet 2007. (Phase-3 double-blind randomized non-inferiority trial)
• [2] Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis — Pappas PG et al., Clinical Infectious Diseases 2007. (Double-blind randomized trial)
• [3] Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation — van Burik JA et al., Clinical Infectious Diseases 2004. (Randomized double-blind trial)
• [4] Micafungin: a new echinocandin — Chandrasekar PH et al., Clinical Infectious Diseases 2006. (Review)
• [5] Echinocandin antifungal drugs — Denning DW et al., Lancet 2003. (Review)

Dosing context

Micafungin is a hospital intravenous antifungal given once daily as a fixed infusion, with the dose selected by indication (treatment versus prophylaxis) and generally not requiring renal dose adjustment.

This is descriptive context only and not a dosing recommendation - antifungal selection, dose and duration are clinician decisions based on the infection, cultures and patient factors.

Side effects & safety profile

Micafungin is generally well tolerated. Key considerations are hepatic - transaminase elevations and, rarely, more serious liver injury - and infusion-related reactions, so it is given as a slow IV infusion.

It has relatively few drug interactions compared with azoles and, importantly, does not usually require dose adjustment in renal impairment. Nephrotoxicity is not a characteristic effect.

It is not approved for aspergillosis, so it should not be substituted for agents with proven mould efficacy when invasive mould infection is suspected.

Stacking & combinations

Echinocandin-based combination antifungal therapy is a specialist, clinician-directed approach for selected severe infections, not a consumer stacking practice.

Finding Micafungin vendors

User reviews

Frequently asked questions

References

1. [1] Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial — Kuse ER et al., Lancet 2007. PMID: 17482982. View sourceStudy: Phase-3 double-blind randomized non-inferiority trialMicafungin was non-inferior to liposomal amphotericin B and better tolerated for invasive candidiasis.
2. [2] Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis — Pappas PG et al., Clinical Infectious Diseases 2007. PMID: 17806055. View sourceStudy: Double-blind randomized trialMicafungin was as effective as caspofungin for candidaemia and invasive candidiasis.
3. [3] Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation — van Burik JA et al., Clinical Infectious Diseases 2004. PMID: 15546073. View sourceStudy: Randomized double-blind trialMicafungin was superior to fluconazole for antifungal prophylaxis during post-transplant neutropenia.
4. [4] Micafungin: a new echinocandin — Chandrasekar PH et al., Clinical Infectious Diseases 2006. PMID: 16575738. View sourceStudy: ReviewReviews micafungin's mechanism, spectrum, pharmacology and favourable safety profile.
5. [5] Echinocandin antifungal drugs — Denning DW et al., Lancet 2003. PMID: 14550704. View sourceStudy: ReviewReviews the echinocandin class, including the beta-1,3-glucan-synthase inhibition shared by micafungin.